Blog
RSS FeedPosted by Michael Wonder on 13 Jun 2017
Institute for Clinical and Economic Review’s “new evidence update” on PCKS9 inhibitors highlights lack of mortality benefit with evolocumab
13 June 2017 - Newly released clinical trial data show expected reductions in stroke and heart attack, but mortality benefit ...